Team Elizabeth Arkema

Our overarching goal is to better understand the causes and consequences of sarcoidosis and lupus. Specifically, our aims are to:

• Identify risk factors for sarcoidosis and lupus
• Reduce the time from symptoms to diagnosis
• Improve treatment strategies for sarcoidosis and lupus
• Minimize the long-term consequences of sarcoidosis and lupus

Our mission is to provide evidence-based answers to etiological and clinical questions using epidemiological methods.

Team Elizabeth Arkema is one of the teams within the research group: Chronic inflammatory disease epidemiology.

Epidemiology of sarcoidosis and systemic lupus erythematosus

We use contemporary Swedish population-based register data to better understand the demographic, clinical and lifestyle factors which drive increased risks of outcomes related to chronic inflammatory diseases, in particular, lupus and sarcoidosis. Our work focuses on quantifying risks so that care for people with lupus and sarcoidoisis can be improved.

Sweden’s high quality and comprehensive healthcare data allow us to conduct large-scale investigations of risk factors for and outcomes after sarcoidosis and lupus. These nationwide data from health and demographic registers form the basis of our data repository for research. It is further enriched by the inclusion of clinical and laboratory data from hospital-based registers.


Elizabeth Arkema

Principal researcher/ Team leader.


Our work brings together the expertise of clinicians, immunologists and epidemiologists. Collaborations are essential for the exchange of expertise from all scientific fields and we welcome researchers interested in chronic inflammatory disease research to contact us.

Research support

Our work is supported by grants from, among others:

  • Swedish Research Council
  • Swedish Heart-Lung Foundation
  • National Institutes of Health
  • Swedish Society for Medicine
  • Strategic Research Area in Epidemiology (SFO Epi)
  • Ingegerd Johansson Foundation
  • Karolinska Institutet Research Foundation

Selected Publications

Sarcoidosis: Epidemiology and clinical insights.
Rossides M, Darlington P, Kullberg S, Arkema EV
J Intern Med 2023 Mar;():

Reproductive and hormonal risk factors for sarcoidosis: a nested case-control study.
Dehara M, Sachs MC, Kullberg S, Grunewald J, Blomberg A, Arkema EV
BMC Pulm Med 2022 Jan;22(1):43

Gestational Diabetes Mellitus Risk in Pregnant Women With Systemic Lupus Erythematosus.
Gernaat SAM, Simard JF, Wikström AK, Svenungsson E, Arkema EV
J Rheumatol 2022 May;49(5):465-469

Risk and predictors of heart failure in sarcoidosis in a population-based cohort study from Sweden.
Rossides M, Kullberg S, Grunewald J, Eklund A, Di Giuseppe D, Askling J, Arkema EV
Heart 2022 Mar;108(6):467-473

Infection hospitalisation in systemic lupus in Sweden.
Simard JF, Rossides M, Gunnarsson I, Svenungsson E, Arkema EV
Lupus Sci Med 2021 Sep;8(1):

Infection risk in sarcoidosis patients treated with methotrexate compared to azathioprine: A retrospective 'target trial' emulated with Swedish real-world data.
Rossides M, Kullberg S, Di Giuseppe D, Eklund A, Grunewald J, Askling J, Arkema EV
Respirology 2021 May;26(5):452-460

Maternal Hypertensive Disorders in Pregnant Women With Systemic Lupus Erythematosus and Future Cardiovascular Outcomes.
Simard JF, Rossides M, Arkema EV, Svenungsson E, Wikström AK, Mittleman MA, Salmon JE
Arthritis Care Res (Hoboken) 2021 Apr;73(4):574-579

Positive Predictive Value of Sarcoidosis Identified in an Administrative Healthcare Registry: A Validation Study.
Ceder S, Rossides M, Kullberg S, Eklund A, Grunewald J, Arkema EV
Epidemiology 2021 May;32(3):444-447

Risk of first and recurrent serious infection in sarcoidosis: a Swedish register-based cohort study.
Rossides M, Kullberg S, Eklund A, Di Giuseppe D, Grunewald J, Askling J, Arkema EV
Eur Respir J 2020 Sep;56(3):

Stroke in systemic lupus erythematosus: a Swedish population-based cohort study.
Arkema EV, Svenungsson E, Von Euler M, Sjöwall C, Simard JF
Ann Rheum Dis 2017 Sep;76(9):1544-1549